given the substantial clinical burden and economic cost of IBD it is important to establish the effectiveness of current medical therapies in both UC and CD
First-pass extracted concept
medical therapies for inflammatory bowel disease
Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
Inflammatory bowel disease imposes substantial clinical and economic burden in the United States.
Quoted textsource-backed
it is estimated that 1.5 million Americans suffer from UC and CD... IBD is responsible for 2.3 million physician visits, 180,000 hospital admissions, and costs $6.3 billion annually.
Both Crohn's disease and ulcerative colitis have a relapsing and remitting course and substantially reduce quality of life during exacerbations.
Quoted textsource-backed
Both UC and CD exhibit a relapsing and remitting course and there is a significant, often dramatic, reduction in quality of life during exacerbations of the disease
Crohn's disease and ulcerative colitis are thought to arise from a disordered immune response to gut contents in genetically predisposed individuals.
Quoted textsource-backed
both are thought to arise from a disordered immune response to the gut contents in genetically predisposed individuals
The review systematically evaluates currently available medical therapies for ulcerative colitis and Crohn's disease for both induction of remission and prevention of relapse.
Quoted textsource-backed
The American College of Gastroenterology IBD Task Force developed a protocol for systematically reviewing the data on currently available therapies for UC and CD, both in inducing remission and in preventing relapse of the disease.